Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Teresa Riva
Observed name:
S.T. Riva
Institutions:
Vita-Salute San Raffaele University,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
Observed institutions:
University of Verona,
Vita-Salute San Raffaele University,
Azienda Ospedaliera Universitaria Integrata Verona,
IRCCS Ospedale San Raffaele,
IRCCS San Raffaele Roma
ORCID:
0000-0002-1107-9055
Observed ORCID:
0000-0002-1107-9055
OpenAlex ID:
A5043555198
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
2023
·
Antonio Nuccio
, Giuseppe Viscardi
, et al.
·
European Journal of Cancer
·
49
PDF
Infections and Immunotherapy in Lung Cancer: A Bad Relationship?
2020
·
Lorenzo Belluomini
, Alberto Caldart
, et al.
·
International Journal of Molecular Sciences
·
43
PDF
Body composition derangements in lung cancer patients treated with first‐line pembrolizumab: A multicentre observational study
2024
·
Ilaria Trestini
, Lorenzo Belluomini
, et al.
·
Journal of Cachexia Sarcopenia and Muscle
·
32
PDF
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic
2020
·
Serena Zuliani
, Ilaria Zampiva
, et al.
·
European Journal of Cancer
·
32
PDF
Integrating supportive care into the multidisciplinary management of lung cancer: we can’t wait any longer
2022
·
Alice Avancini
, Lorenzo Belluomini
, et al.
·
Expert Review of Anticancer Therapy
·
21
Cardiac autonomic dysfunction in patients with cancer: exploring the role of physical exercise
2025
·
Anita Borsati
, Linda Toniolo
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
13
PDF
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience
2024
·
Francesca Rita Ogliari
, Alberto Traverso
, et al.
·
Lung Cancer
·
7
Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
2021
·
Lorenzo Belluomini
, Silvia Teresa Riva
, et al.
·
Cells
·
6
PDF
Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Immunotherapy Induction
2021
·
Lorenzo Belluomini
, Valeria Dionisi
, et al.
·
Clinical Lung Cancer
·
6
Primary melanoma of the gastrointestinal tract
2026
·
Paola De Nardi
, Stefania Guida
, et al.
·
World Journal of Gastroenterology
·
5
Bone metastases in NSCLC: Modern paradigms in management and supportive care
2025
·
Gabriele Minuti
, Giorgia Pasqualini
, et al.
·
Cancer Treatment Reviews
·
5
PDF
Impact of platinum-based chemotherapy and CTLA-4 inhibition on acquired resistance to first-line anti-PD-1/PD-L1 agents in non-small cell lung cancer: a systematic review and reconstructed individual patient data analysis
2025
·
Sara Oresti
, Fabio Salomone
, et al.
·
EClinicalMedicine
·
5
PDF
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study
2025
·
Alice Avancini
, Niccolò Giaj-Levra
, et al.
·
Lung Cancer
·
5
55P EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
2023
·
S.T. Riva
, F.R. Ogliari
, et al.
·
ESMO Open
·
3
PDF
1701P Oncological patients’ perception of infection risks and level of acceptance of protective measures during SARS-CoV-2 pandemic
2020
·
D. Tregnago
, S. Zuliani
, et al.
·
Annals of Oncology
·
2
PDF
Clinicogenomic determinants of early progression on first-line osimertinib in EGFR -mutant NSCLC.
2026
·
Federica Pecci
, Mark Yungjie Jeng
, et al.
·
Journal of Clinical Oncology
·
1
P1.11.01 First-Line Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metastatic NSCLC: Real World Data in Italy
2025
·
F. Agustoni
, G. Gambini
, et al.
·
Journal of Thoracic Oncology
·
1
1232P Assessing uncertainty and vulnerability of clinical trials with immune-checkpoint inhibitors and chemotherapy (ICI+CT) in early stage non-small cell lung cancer (NSCLC) by informative censoring and survival inferred fragility index (SIFI)
2024
·
A. Nuccio
, F. Salomone
, et al.
·
Annals of Oncology
·
1
PDF
1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy
2020
·
S. Merler
, S. Zuliani
, et al.
·
Annals of Oncology
·
1
PDF
Clinicogenomic determinants of early progression on first-line osimertinib in EGFR-mutant NSCLC
2026
·
Federica Pecci
, Mark Y. Jeng
, et al.
·
Journal of Thoracic Oncology
Hyperprogression Upon Cemiplimab Alone or With Short Course Chemotherapy in PD-L1 ≥ 50% Non–small Cell Lung Cancer: A Biomarker Guided Multicenter International Phase 2 Trial—HYPERBOLIC Study
2026
·
Ludovica Mollica
, Elena Tassi
, et al.
·
Clinical Lung Cancer
PP01.20: Integrating Clinicopathologic and Genomic Features to Identify Patients at Risk of Earlier Progression to First-Line Osimertinib in EGFR-Mutant NSCLC
2026
·
Federica Pecci
, Mark Jeng
, et al.
·
Journal of Thoracic Oncology
562eP Tumor, host and treatment related predictive factors for immune-related adverse events (irAEs) in non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI)
2026
·
F.M. Venanzi
, D. Zotti
, et al.
·
ESMO Open
A viable human lung cancer tissue collection (LCTC) to accelerate translational research
2026
·
Virginia Guzzeloni
, Alessandra Bartolucci
, et al.
·
Cancer Treatment and Research Communications
37P EGFR variant allele frequency (VAF) on tissue is a prognostic factor for patients with advanced non-small cell lung cancer (aNSCLC) treated with first-line osimertinib (osi): Results from ATLAS network
2025
·
S.T. Riva
, A. Vitale
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
30
Citation count:
238
H-index:
7
I10-index:
6
Year
Topic
Type